Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388614 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL2052804 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL14691142 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL15353311 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL14691208 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL9184494 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL15353310 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL10389648 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL8583827 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 | |
| SCHEMBL14690912 | 1.00 | GAA (0.53) | GAAL3MBTL1MAPTMAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-05-11 | — | — | US | disclosed |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-03-09 | — | — | US | disclosed |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2020-05-07 | — | — | US | disclosed |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENRESE (IT) | 2019-04-04 | — | — | US | disclosed |
| WO-2017182340-A1 | USE OF O-GLYCOSYLATED INDOLE OR INDOLINE DERIVATIVE WITH GLYCOSIDASE FOR DEYING KERATIN FIBERS | L'OREAL (FR) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | DDX3X, DDX21, DDB1 | GAA 2503/4885L3MBTL1 1706/4885MAPT 4194/4885 |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | GAA 1584/4885L3MBTL1 669/4885MAPT 3432/4885 |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | DDX3X, DDX39B, DDX1 | GAA 1584/4885L3MBTL1 669/4885MAPT 3432/4885 |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | DDX21, DDX3X, DDB1 | GAA 2407/4885L3MBTL1 1528/4885MAPT 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.